CRISPR Therapeutics AG (CRSP)
Nasdaq · Healthcare · Biotechnology
$57.34+3.45%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $5.5B
- 52-week range
- $44.12 – $78.48
- 52-week change
- −21.51%
- EPS (trailing)
- −$4.74
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $3.5M (−90.59%)
- Net income
- −$582M
- Operating margin
- −18933.6%
- Diluted EPS
- −$6.47
- Free cash flow
- −$346M
From the company’s annual report on SEC EDGAR.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
Headquarters: Zug, Switzerland · crisprtx.com